Gene G. Kinney - Aug 17, 2022 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role
President and CEO
Signature
/s/ Michael Malecek, as Attorney in Fact for Gene G. Kinney
Stock symbol
PRTA
Transactions as of
Aug 17, 2022
Transactions value $
-$55,874
Form type
4
Date filed
8/19/2022, 09:30 PM
Previous filing
Aug 12, 2022
Next filing
Sep 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $14K +2.18K +17.05% $6.41* 15K Aug 17, 2022 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$69.9K -2.18K -14.57% $32.03 12.8K Aug 17, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (Right to Buy) Options Exercise $0 -2.18K -10.23% $0.00 19.1K Aug 17, 2022 Ordinary Shares 2.18K $6.41 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $32.00 to $32.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.
F4 The Reporting Person holds options that give him the right to acquire an aggregate of 2,023,832 shares at exercise prices ranging from $6.41 to $32.45, of which 1,497,476 are currently exercisable, and 526,356 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award.